Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.
Proteolytic activity is required for several key processes in cancer development and progression, including tumor growth, invasion and metastasis. Accordingly, high levels of protease expression and activity have been found to correlate with malignant progression and poor patient prognosis in a wide variety of human cancers. Members of the papain family of cysteine cathepsins are among the protease classes that have been functionally implicated in cancer. Therefore, the discovery of effective cathepsin inhibitors has considerable potential for anti-cancer therapy. In this study we describe the identification of a novel, reversible cathepsin inhibitor, VBY-825, which has high potency against cathepsins B, L, S and V. VBY-825 was tested in a pre-clinical model of pancreatic islet cancer and found to significantly decrease tumor burden and tumor number. Thus, the identification of VBY-825 as a new and effective anti-tumor drug encourages the therapeutic application of cathepsin inhibitors in cancer.
Elie
Benelita Tina
BT
Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Gocheva
Vasilena
V
Shree
Tanaya
T
Dalrymple
Stacie A
SA
Holsinger
Leslie J
LJ
Joyce
Johanna A
JA
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001682:Biological Availability; D002403:Cathepsins / Q000037:antagonists & inhibitors*; D049109:Cell Proliferation / Q000187:drug effects; D003521:Cyclopropanes; D004195:Disease Models, Animal; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology*; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic; D010190:Pancreatic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011480:Protease Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D013450:Sulfones / Q000494:pharmacology*; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D003521:Cyclopropanes; D006845:Hydrocarbons, Fluorinated; C404948:JPM 565; D011480:Protease Inhibitors; D013450:Sulfones; C555884:VBY-825; D002403:Cathepsins; D007930:Leucine
Curr Pharm Des. 2007;13(4):387-403
17311556
Nat Rev Cancer. 2006 Mar;6(3):227-39
16498445
Cancer Cell. 2004 May;5(5):443-53
15144952
Annu Rev Cell Dev Biol. 2009;25:567-95
19575644
Biol Chem. 2007 May;388(5):541-5
17516850
Adv Drug Deliv Rev. 2005 May 25;57(7):973-93
15876399
Cancer Cell. 2002 May;1(4):339-53
12086849
Cancer Res. 2009 May 15;69(10):4537-44
19435903
Mol Cancer Ther. 2008 Mar;7(3):538-47
18347141
Leukemia. 2007 Jan;21(1):44-52
16990761
Circ Res. 2003 Mar 21;92(5):493-500
12600886
Genes Dev. 2006 Mar 1;20(5):543-56
16481467
Biol Chem. 2008 Aug;389(8):1067-74
18710344
Clin Cancer Res. 2009 Oct 1;15(19):6042-51
19789302
Trends Pharmacol Sci. 2008 Jan;29(1):22-8
18037508
Cancer Res. 2004 Jan 1;64(1):146-51
14729618
Biol Chem. 2010 Aug;391(8):937-45
20731543
Cancer Res. 2006 May 15;66(10):5242-50
16707449
Nat Rev Drug Discov. 2006 Sep;5(9):785-99
16955069
Immunity. 1999 Feb;10(2):207-17
10072073
Protein Sci. 1998 Jun;7(6):1294-302
9655332
Cancer Res. 2007 Oct 15;67(20):9894-902
17942921
Anal Biochem. 2004 Dec 15;335(2):218-27
15556560
J Biol Chem. 2006 Mar 3;281(9):6020-9
16365041
Biochimie. 2010 Nov;92(11):1681-8
20346385
J Clin Invest. 1998 Jun 1;101(11):2351-63
9616206
Nat Rev Cancer. 2006 Oct;6(10):764-75
16990854
Chem Biol. 2007 May;14(5):499-511
17524981
Cancer Cell. 2002 Mar;1(2):193-202
12086877
Curr Cancer Drug Targets. 2009 Feb;9(1):32-71
19200050
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2497-502
20133781
Genes Dev. 2010 Feb 1;24(3):241-55
20080943
Clin Exp Metastasis. 1997 Mar;15(2):121-9
9062388
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14404-9
16183744
Curr Opin Support Palliat Care. 2008 Sep;2(3):218-22
18685424
Cancer Res. 2007 Aug 1;67(15):7378-85
17671208
Immunity. 1999 Feb;10(2):197-206
10072072
Nature. 1985 May 9-15;315(6015):115-22
2986015
IDrugs. 2009 Dec;12(12):799-809
19943223
Curr Opin Drug Discov Devel. 2006 Jul;9(4):471-82
16889230
Biol Chem. 2004 Nov;385(11):1017-27
15576321
J Med Chem. 1996 Aug 16;39(17):3357-66
8765519
Anticancer Res. 2009 Nov;29(11):4473-81
20032394
Expert Opin Investig Drugs. 2009 May;18(5):585-600
19388876
Curr Top Med Chem. 2010;10(3):294-322
20166952